Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Teva
Healthtrust
Moodys
UBS
QuintilesIMS
Colorcon
Johnson and Johnson
Cerilliant

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,529,596

« Back to Dashboard

Summary for Patent: 4,529,596
Title: Thieno [3,2-c] pyridine derivatives and their therapeutic application
Abstract:This invention relates to new thieno [3,2-c] pyridine derivatives having the formula: ##STR1## in which: Y represents the OH group or an OR group in which R is a straight or branched lower alkyl radical, or Y represents a group ##STR2## in which R.sub.1 and R.sub.2 are each independently of each other, hydrogen or a straight or branched lower alkyl group; or R.sub.1 and R.sub.2 form together and with the nitrogen atom to which they are attached a heterocycle which may include a second heteroatom such as oxygen or nitrogen, wherein the latter may be substituted by a lower alkyl or benzyl radical which may be substituted; and X represents hydrogen, a halogen or a lower alkyl radical; and their addition salts with pharmaceutically acceptable mineral or organic acids if Y represents the group OR or ##STR3## or with mineral bases if Y represents OH, as well as the two enantiomers or their mixture. The invention also relates to the preparation process of new thieno [3,2-c] pyridine derivatives and to their therapeutic application as blood-platelet aggregation inhibiting agents and antithrombotics.
Inventor(s): Aubert; Daniel (Plaisance Du Touch, FR), Ferrand; Claude (Ramonville Saint-Agne, FR), Maffrand; Jean-Pierre (Garonne, FR)
Assignee: Sanofi, S.A. (Toulouse, FR)
Application Number:06/510,582
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Dosage form;

Drugs Protected by US Patent 4,529,596

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 4,529,596

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France82 12599Jul 13, 1982

International Patents Family Members for US Patent 4,529,596

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 25384 ➤ Subscribe
Australia 1663783 ➤ Subscribe
Australia 554358 ➤ Subscribe
Canada 1194875 ➤ Subscribe
Czechoslovakia 246062 ➤ Subscribe
Czechoslovakia 246082 ➤ Subscribe
Czechoslovakia 8305281 ➤ Subscribe
Czechoslovakia 8403815 ➤ Subscribe
German Democratic Republic 211351 ➤ Subscribe
Germany 3369683 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Merck
US Department of Justice
Express Scripts
Johnson and Johnson
Covington
Citi
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot